Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 26 of 34

Key U.S. Food and Drug Administration-Issued Information on Medications Used To Treat Hepatitis C Virus Infection (2 of 2)

Some medications used to treat hepatitis C virus infections carry warnings for potential drug-drug interactions that might occur with their use. These warnings have been issued by the U.S. Food and Drug Administration. The medications that carry such warnings include boceprevir and telaprevir.

Boceprevir carries a warning that it is contraindicated in coadministration with drugs that are dependent on CYP3A4/5 for clearance and for which elevated plasma concentrations are associated with serious or life-threatening events. Boceprevir is also contraindicated in coadministration with potent CYP3A4/5 inducers, where significantly reduced boceprevir plasma concentrations may be associated with reduced efficacy.

Telaprevir carries a warning that it is contraindicated in coadministration with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Telaprevir is also contraindicated in coadministration with drugs that strongly induce CYP3A, which may lead to lower exposure and loss of efficacy of telaprevir.